BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28034324)

  • 1. P16 overexpression in BRAF-mutated gastrointestinal stromal tumors.
    Shi SS; Wang X; Xia QY; Rao Q; Shen Q; Ye SB; Li R; Shi QL; Lu ZF; Ma HH; Zhou XJ
    Expert Rev Mol Diagn; 2017 Feb; 17(2):195-201. PubMed ID: 28034324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
    Huss S; Pasternack H; Ihle MA; Merkelbach-Bruse S; Heitkötter B; Hartmann W; Trautmann M; Gevensleben H; Büttner R; Schildhaus HU; Wardelmann E
    Hum Pathol; 2017 Apr; 62():206-214. PubMed ID: 28159677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
    Agaimy A; Terracciano LM; Dirnhofer S; Tornillo L; Foerster A; Hartmann A; Bihl MP
    J Clin Pathol; 2009 Jul; 62(7):613-6. PubMed ID: 19561230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors.
    Jasek K; Buzalkova V; Minarik G; Stanclova A; Szepe P; Plank L; Lasabova Z
    Virchows Arch; 2017 Jan; 470(1):29-36. PubMed ID: 27864688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
    Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
    Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF mutations in KIT/PDGFRA positive gastrointestinal stromal tumours (GISTs): Is their frequency underestimated?
    Jašek K; Váňová B; Grendár M; Štanclová A; Szépe P; Hornáková A; Holubeková V; Plank L; Lasabová Z
    Pathol Res Pract; 2020 Nov; 216(11):153171. PubMed ID: 32836055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
    Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
    Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple sporadic gastrointestinal stromal tumours arising at different gastrointestinal sites: pattern of involvement of the muscularis propria as a clue to independent primary GISTs.
    Agaimy A; Märkl B; Arnholdt H; Wünsch PH; Terracciano LM; Dirnhofer S; Hartmann A; Tornillo L; Bihl MP
    Virchows Arch; 2009 Aug; 455(2):101-8. PubMed ID: 19572146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of BRAF V600E mutation-specific immunohistochemistry in detecting BRAF V600E-mutated gastrointestinal stromal tumors.
    Patil DT; Ma S; Konishi M; Carver PD; Pukay M; Beadling C; Corless CL; Rubin BP
    Am J Clin Pathol; 2015 Nov; 144(5):782-9. PubMed ID: 26486743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A smooth muscle-derived, Braf-driven mouse model of gastrointestinal stromal tumor (GIST): evidence for an alternative GIST cell-of-origin.
    Kondo J; Huh WJ; Franklin JL; Heinrich MC; Rubin BP; Coffey RJ
    J Pathol; 2020 Dec; 252(4):441-450. PubMed ID: 32944951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF mutation status in gastrointestinal stromal tumors.
    Hostein I; Faur N; Primois C; Boury F; Denard J; Emile JF; Bringuier PP; Scoazec JY; Coindre JM
    Am J Clin Pathol; 2010 Jan; 133(1):141-8. PubMed ID: 20023270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Application of BRAF V600E mutation-specific immunohistochemistry in diagnosis of gastrointestinal stromal tumors].
    Shi SS; Wang X; Xia QY; Lu ZF; Ye SB; Yang WR; Li R; Ma HH; Rao Q; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2016 Aug; 45(8):566-70. PubMed ID: 27510784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs.
    Martinho O; Gouveia A; Viana-Pereira M; Silva P; Pimenta A; Reis RM; Lopes JM
    Histopathology; 2009 Jul; 55(1):53-62. PubMed ID: 19614767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR gene mutation in gastrointestinal stromal tumours.
    Shi SS; Wu N; He Y; Wei X; Xia QY; Wang X; Ye SB; Li R; Rao Q; Zhou XJ
    Histopathology; 2017 Oct; 71(4):553-561. PubMed ID: 28485054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal stromal tumors with BRAF gene fusions. A report of two cases showing low or absent KIT expression resulting in diagnostic pitfalls.
    Torrence D; Xie Z; Zhang L; Chi P; Antonescu CR
    Genes Chromosomes Cancer; 2021 Dec; 60(12):789-795. PubMed ID: 34398495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study.
    Rossi S; Gasparotto D; Miceli R; Toffolatti L; Gallina G; Scaramel E; Marzotto A; Boscato E; Messerini L; Bearzi I; Mazzoleni G; Capella C; Arrigoni G; Sonzogni A; Sidoni A; Mariani L; Amore P; Gronchi A; Casali PG; Maestro R; Dei Tos AP
    Am J Surg Pathol; 2015 Jul; 39(7):922-30. PubMed ID: 25970686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastric GISTs: Analysis of c-Kit, PDGFRA and BRAF mutations in relation to prognosis and clinical pathological characteristics of patients - A GIRCG study.
    Capelli L; Petracci E; Quagliuolo V; Saragoni L; Colombo P; Morgagni P; Calistri D; Tomezzoli A; Di Cosmo M; Roviello F; Vindigni C; Coniglio A; Villanacci V; Catarci M; Coppola L; Alfieri S; Ricci R; Capella C; Rausei S; Gulino D; Amadori D; Ulivi P;
    Eur J Surg Oncol; 2016 Aug; 42(8):1206-14. PubMed ID: 27265040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic significance of DOG-1 and PKC-θ expression and c-Kit/PDGFRA mutations in gastrointestinal stromal tumours.
    Wang C; Jin MS; Zou YB; Gao JN; Li XB; Peng F; Wang HY; Wu ZD; Wang YP; Duan XM
    Scand J Gastroenterol; 2013 Sep; 48(9):1055-65. PubMed ID: 23862765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST).
    Daniels M; Lurkin I; Pauli R; Erbstösser E; Hildebrandt U; Hellwig K; Zschille U; Lüders P; Krüger G; Knolle J; Stengel B; Prall F; Hertel K; Lobeck H; Popp B; Theissig F; Wünsch P; Zwarthoff E; Agaimy A; Schneider-Stock R
    Cancer Lett; 2011 Dec; 312(1):43-54. PubMed ID: 21906875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exon 11 mutations, Ki67, and p16(INK4A) as predictors of prognosis in patients with GIST.
    Cerski MR; Pereira F; Matte US; Oliveira FH; Crusius FL; Waengertner LE; Osvaldt A; Fornari F; Meurer L
    Pathol Res Pract; 2011 Nov; 207(11):701-6. PubMed ID: 22024151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.